Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,783.00
(
0.38%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biopearl post# 9178

Friday, 03/14/2008 5:57:20 PM

Friday, March 14, 2008 5:57:20 PM

Post# of 19309
Re: Merrimack

>The take away is #1. Not enough side effects to stop the study #2. Enough efficacy that patients are willing to continue in the open label arm. #3. Continued demand for product from our goats.<

The appeal of MM-093 relative to other biologics for RA has always been its excellent tolerability. If the efficacy is there, MM-093 ought to be a serious player, at least in the second-line setting.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today